| First Author | Engels B | Year | 2013 |
| Journal | Cancer Cell | Volume | 23 |
| Issue | 4 | Pages | 516-26 |
| PubMed ID | 23597565 | Mgi Jnum | J:197038 |
| Mgi Id | MGI:5490687 | Doi | 10.1016/j.ccr.2013.03.018 |
| Citation | Engels B, et al. (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23(4):516-26 |
| abstractText | Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy. |
